On May 19, 2025, the first patient was dosed in the IDeate-Esophageal01 Phase 3 trial, evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd). This antibody-drug conjugate (ADC) is being developed by Merck and Daiichi Sankyo.
The trial compares I-DXd against investigator’s choice of chemotherapy in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC). These patients have experienced disease progression following treatment with platinum-containing systemic therapy and an immune checkpoint inhibitor.
This advancement into late-stage development for a novel ADC in a difficult-to-treat cancer highlights Merck's focus on innovative oncology solutions. The trial aims to address the low overall survival rates associated with this disease.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.